Ocuphire announced its phase II clinical trial poster was presented at the 83rd Scientific Sessions of the American...
Optum Rx to place Boehringer’s Cyltezo® (interchangeable adalimumab) on its formulary as preferred brand
Boehringer Ingelheim announced that Optum Rx, pharmacy benefit manager, will place Cyltezo® (adalimumab-adbm), the...
ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel eblasakimab
ASLAN Pharmaceuticals announced that it entered an exclusive licence with Zenyaku Kogyo to develop and commercialise...
Samsung Bioepis files IPR against Alexion alleging invalidity of Soliris® (eculizumab) patent
Samsung Bioepis has filed an IPR in the US against Alexion’s Soliris® (eculizumab) patent 10,703,809 (’809 patent)...
Samsung Bioepis files IPR against Janssen alleging invalidity of Stelara® (ustekinumab) patent
Samsung Bioepis has filed an IPR against Janssen’s US patent no. 10,961,307 (‘307 patent) relating to Stelara®...
FDA accepts Xbrane’s sBLA for biosimilar ranibizumab
Xbrane Biopharma announced the FDA has accepted a supplemental Biologics License Application (sBLA) for its biosimilar...
LOTTE Biologics announces four-party MOU to build three biologics plants
LOTTE Biologics announced it has signed a memorandum of understanding with LOTTE Corporation, Incheon Metropolitan...
Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to Stelara®) in Brazil
BusinessWire reports that Bio-Thera Solutions and Biomm SA have reached a licensing and supply agreement for BAT2206...
Merck acquires Prometheus Biosciences
Merck announced that it has acquired Prometheus Biosciences, Inc. which is now a wholly-owned subsidiary of Merck. ...
Glenmark provides 70% price drop for breast cancer drug Trumab®, biosimilar trastuzumab
The Economic Times in India reported that Glenmark provided a drastic price drop in India for Trumab® (trastuzumab),...
Approval alert: Genentech’s Columvi® (glofitamab) approved for R/R DLBCL by FDA
Genentech announced that the FDA approved Columvi® (glofitamab-gxbm) for the treatment of adults with relapsed or...
Sandoz announces Act4Biosimilars Action Plan to improve access to biosimilars
Sandoz announced its new Act4Biosmilars Action Plan as part of its Act4Biosimilars initiative that aims to increase...
AbbVie and Coherus resolve breach of contract dispute over adalimumab
Coherus has confirmed in a Form 8-K filed with the SEC that it has resolved its recent dispute with AbbVie relating to...
Pfizer withdraws notification for US$43B acquisition of Seagen after FTC sues to block Amgen’s M&A deal
Seagen’s SEC filing has disclosed that Pfizer withdrew its notification to the Federal Trade Commission (FTC) and...
Celltrion to apply for approval of five new biosimilars by the end of 2023
The Korea Economic Daily reports that Celltrion announced it intends to apply for regulatory approval of five new...
New indication alert: NMPA approves AZ/Alexion’s Soliris® (eculizumab) for gMG
AstraZeneca announced that the Chinese NMPA has approved Soliris® (eculizumab) for treatment of refractory generalised...